OSTEOP
MCID: OST002
MIFTS: 79

Osteoporosis (OSTEOP)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Osteoporosis

MalaCards integrated aliases for Osteoporosis:

Name: Osteoporosis 57 12 75 74 37 55 6 43 44 15 38 63 40 17 72
Postmenopausal Osteoporosis 74 29 6 17 33
Osteoporosis, Postmenopausal 57 72
Osteoporosis, Involutional 57 13
Bone Mineral Density Quantitative Trait Locus; Bmnd 57
Bone Mineral Density Variation Qtl, Osteoporosis 57
Bone Mineral Density, Quantitative Trait Locus 40
Bone Mineral Density Quantitative Trait Locus 57
Osteoporosis, Postmenopausal, Susceptibility 57
Osteoporosis, Susceptibility to 57
Osteoporosis Postmenopausal 55
Involutional Osteoporosis 74
Osteoporosis, Senile 72
Senile Osteoporosis 74
Osteop 74
Bmnd 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
osteoporosis:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:11476
OMIM 57 166710
KEGG 37 H01593
ICD9CM 35 733.0 733.00
MeSH 44 D010024
NCIt 50 C3298
SNOMED-CT 68 64859006
UMLS 72 C0029456 C0029458 C0029459

Summaries for Osteoporosis

KEGG : 37
Osteoporosis is a common disease characterised by a generalised reduction in bone mineral density (BMD), microarchitectural deterioration of bone tissue and an increased risk of fracture. Since BMD values fall progressively with age, the prevalence of osteoporosis increases with age. It has been estimated that approximately 50% of all women will have osteoporosis by the age of 80. Studies in twins and families indicate that genetic factors play an important role in the regulation of BMD and other determinants of osteoporotic fracture risk. Osteoporosis is a polygenic disorder, determined by the effects of several genes, each with relatively modest effects. Population-based studies and case-control studies have similarly identified polymorphisms in several candidate genes that have been associated with bone mass or osteoporotic fracture, including the vitamin D receptor, oestrogen receptor and collagen gene. Bisphosphonates, and in some patients denosumab, are first-line drugs for osteoporosis.

MalaCards based summary : Osteoporosis, also known as postmenopausal osteoporosis, is related to osteoporosis, juvenile and glucocorticoid-induced osteoporosis, and has symptoms including tremor, angina pectoris and back pain. An important gene associated with Osteoporosis is COL1A1 (Collagen Type I Alpha 1 Chain), and among its related pathways/superpathways are Osteoclast differentiation and Mineral absorption. The drugs Linagliptin and Magnesium oxide have been mentioned in the context of this disorder. Affiliated tissues include Bone and Bone, and related phenotypes are osteoporosis and hematopoietic system

Disease Ontology : 12 A bone resorption disease characterized by decreased density of normally mineralized bone which results in the thinning of bone tissue and decreased mechanical strength.

MedlinePlus : 43 Osteoporosis is a disease that thins and weakens the bones. Your bones become fragile and break easily, especially the bones in the hip, spine, and wrist. In the United States, millions of people either already have osteoporosis or are at high risk due to low bone mass. Anyone can develop osteoporosis, but it is more common in older women. Risk factors include Getting older Being small and thin Having a family history of osteoporosis Taking certain medicines Being a white or Asian woman Having low bone density Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health. To keep bones strong, eat a diet rich in calcium and vitamin D, exercise, and do not smoke. If needed, medicines can also help. It is also important to try to avoid falling down. Falls are the number one cause of fractures in older adults. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

UniProtKB/Swiss-Prot : 74 Osteoporosis: A systemic skeletal disorder characterized by decreased bone mass and deterioration of bone microarchitecture without alteration in the composition of bone. The result is fragile bones and an increased risk of fractures, even after minimal trauma. Osteoporosis is a chronic condition of multifactorial etiology and is usually clinically silent until a fracture occurs.

PubMed Health : 63 About osteoporosis: Having weak bones that easily break is a sign of osteoporosis. It is normal for your bones to become less dense as you grow older, but osteoporosis speeds up this process. This condition can particularly lead to problems in older age because broken bones do not heal as easily in older people as they do in young people, and the consequences are more serious. In general, osteoporosis is more common in women, and they often develop it at a younger age. Getting older does not mean that you will automatically develop osteoporosis, but the risk does increase with age. People over the age of 70 are more likely to have low bone density. Plus, the risk of falling increases in old age, which then also makes fractures more likely. But there are several things you can do to protect and strengthen your bones – even if you are already older.

Wikipedia : 75 Osteoporosis is a disease in which bone weakening increases the risk of a broken bone. It is the most... more...

More information from OMIM: 166710

Related Diseases for Osteoporosis

Diseases in the Osteoporosis family:

Osteoporosis, Juvenile Juvenile Primary Osteoporosis

Diseases related to Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1082)
# Related Disease Score Top Affiliating Genes
1 osteoporosis, juvenile 36.3 WNT1 LRP5 COL1A1 CALCA BGLAP
2 glucocorticoid-induced osteoporosis 35.9 TNFSF11 TNFRSF11B RUNX2 CALCA BGLAP
3 bone mineral density quantitative trait locus 15 35.0 PDLIM4 CALCR
4 bone disease 34.3 VDR TNFSF11 TNFRSF11B TNFRSF11A RUNX2 LRP5
5 hyperparathyroidism 34.1 VDR TNFRSF11B CALCA BGLAP
6 bone resorption disease 34.0 VDR TNFSF11 TNFRSF11B TNFRSF11A RUNX2 LRP5
7 osteopetrosis 33.8 TNFSF11 TNFRSF11A LRP5
8 osteogenesis imperfecta, type viii 33.1 COL1A2 COL1A1
9 osteonecrosis 33.1 TNFSF11 TNFRSF11B RUNX2 BGLAP
10 osteomalacia 32.9 VDR CALCA BGLAP
11 periodontitis 32.7 TNFSF11 TNFRSF11B RUNX2 BGLAP
12 brittle bone disorder 32.6 COL1A2 COL1A1 BGLAP
13 primary hyperparathyroidism 32.5 VDR CALCA BGLAP
14 sclerosteosis 32.5 VDR RUNX2 LRP5 COL1A1
15 paget's disease of bone 32.4 TNFSF11 TNFRSF11B TNFRSF11A CALCA BGLAP
16 renal osteodystrophy 32.3 VDR TNFRSF11B CALCA BGLAP
17 endosteal hyperostosis, autosomal dominant 32.1 TNFSF11 TNFRSF11B LRP5
18 hyperostosis 32.0 TNFRSF11B LRP5 COL1A1
19 idiopathic hypercalciuria 32.0 VDR TNFSF11 BGLAP
20 bone inflammation disease 31.9 TNFSF11 TNFRSF11B BGLAP
21 ankylosis 31.9 TNFRSF11B RUNX2 BGLAP
22 van buchem disease 31.8 VDR LRP5 COL1A1
23 osteogenesis imperfecta, type i 31.7 TNFRSF11B COL1A2 COL1A1 BGLAP
24 hemophilic arthropathy 31.7 TNFSF11 TNFRSF11B TNFRSF11A
25 otosclerosis 31.6 TNFRSF11B COL1A2 COL1A1
26 periodontitis, chronic 31.6 TNFSF11 TNFRSF11B
27 parathyroid adenoma 31.6 VDR CALCA BGLAP
28 secondary hyperparathyroidism of renal origin 31.5 VDR TNFRSF11B CALCA BGLAP
29 bone cancer 31.5 TNFSF11 TNFRSF11A ESR1 COL1A1
30 dental fluorosis 31.4 ESR1 COL1A2 BGLAP
31 giant cell tumor 31.3 TNFSF11 TNFRSF11B TNFRSF11A CALCA BGLAP
32 osteogenesis imperfecta, type iii 31.3 WNT1 COL1A2 COL1A1 BGLAP
33 osteitis fibrosa 31.3 CALCA BGLAP
34 craniodiaphyseal dysplasia 31.2 WNT1 LRP5 CALCA
35 protrusio acetabuli 31.1 VDR ESR1
36 kummell's disease 31.0 TNFSF11 TNFRSF11B
37 ossification of the posterior longitudinal ligament of spine 30.4 RUNX2 BGLAP
38 hypercalcemia, infantile, 1 30.3 VDR CALCA
39 bone mineral density quantitative trait locus 9 12.8
40 bone mineral density quantitative trait locus 10 12.8
41 bone mineral density quantitative trait locus 11 12.8
42 bone mineral density quantitative trait locus 13 12.8
43 bone mineral density quantitative trait locus 14 12.8
44 osteoporosis-pseudoglioma syndrome 12.8
45 bone mineral density quantitative trait locus 4 12.7
46 bone mineral density quantitative trait locus 5 12.7
47 bone mineral density quantitative trait locus 6 12.7
48 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.6
49 juvenile primary osteoporosis 12.6
50 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.5

Comorbidity relations with Osteoporosis via Phenotypic Disease Network (PDN): (show top 50) (show all 84)


Active Peptic Ulcer Disease Acute Cor Pulmonale
Acute Cystitis Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Asthma
Benign Essential Hypertension Bronchiectasis
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Pulmonary Heart Disease
Chylomicron Retention Disease Conjunctivitis
Conn's Syndrome Cystitis
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Femoral Vein Thrombophlebitis Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hyperparathyroidism
Hypertension, Essential Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypothyroidism Idiopathic Interstitial Pneumonia
Inflammatory Bowel Disease 1 Intervertebral Disc Disease
Intestinal Obstruction Iron Deficiency Anemia
Irritable Bowel Syndrome Macular Degeneration, Age-Related, 1
Major Depressive Disorder Marasmus
Monoclonal Paraproteinemia Neurogenic Bladder
Nutritional Deficiency Disease Opioid Addiction
Oral Candidiasis Osteoarthritis

Graphical network of the top 20 diseases related to Osteoporosis:



Diseases related to Osteoporosis

Symptoms & Phenotypes for Osteoporosis

Human phenotypes related to Osteoporosis:

32
# Description HPO Frequency HPO Source Accession
1 osteoporosis 32 HP:0000939

Symptoms via clinical synopsis from OMIM:

57
Skel:
postmenopausal osteoporosis

Clinical features from OMIM:

166710

UMLS symptoms related to Osteoporosis:


tremor, angina pectoris, back pain, sciatica, equilibration disorder, muscle cramp, pelvic pain

MGI Mouse Phenotypes related to Osteoporosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 CALCR COL1A1 ESR1 LRP5 RUNX2 TNFRSF11A
2 craniofacial MP:0005382 9.97 COL1A1 LRP5 RUNX2 TNFRSF11A TNFRSF11B TNFSF11
3 immune system MP:0005387 9.96 CALCR COL1A1 ESR1 LRP5 RUNX2 TNFRSF11A
4 limbs/digits/tail MP:0005371 9.85 CALCR COL1A1 COL1A2 ESR1 LRP5 RUNX2
5 muscle MP:0005369 9.5 COL1A1 COL1A2 ESR1 RUNX2 TNFSF11 VDR
6 skeleton MP:0005390 9.36 CALCR COL1A1 COL1A2 ESR1 LRP5 RUNX2

Drugs & Therapeutics for Osteoporosis

PubMed Health treatment related to Osteoporosis: 63

Even if someone already has osteoporosis, it is important for them to do regular exercise and get enough calcium and vitamin D. In Germany, statutory health insurances cover the cost of calcium or vitamin D supplements if a doctor has prescribed them. Osteoporosis can be treated with several drugs designed to slow bone loss and increase the production of new bone tissue. These include bisphosphonates and some hormonal or hormone-like medications. These kinds of drugs can have different types of side effects, though, and may not be suitable for everyone. They are only considered if someone has already broken a bone, or if their risk of bone fractures is high – for example, if their bone density is very low or if they have a combination of different risk factors, like low body weight, old age and a higher risk of falling. Hormone products, like those used to treat menopause symptoms, can also lower the risk of osteoporosis-related bone fractures when taken over the long term. But long-term hormone therapy during or after menopause increases the risk of cardiovascular diseases and breast cancer. For this reason it is only rarely recommended as treatment for osteoporosis. The pros and cons of this treatment should be carefully weighed.

Drugs for Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 647)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4 668270-12-0 10096344
2
Magnesium oxide Approved Phase 4 1309-48-4 14792
3
Dinoprostone Approved Phase 4 363-24-6 5280360
4
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
5
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Tibolone Approved, Investigational Phase 4 5630-53-5
11
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
12
Acetaminophen Approved Phase 4 103-90-2 1983
13
Atorvastatin Approved Phase 4 134523-00-5 60823
14
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
15
Etanercept Approved, Investigational Phase 4 185243-69-0
16
Pamidronate Approved Phase 4 40391-99-9 4674
17
Montelukast Approved Phase 4 158966-92-8 5281040
18
Adalimumab Approved Phase 4 331731-18-1 16219006
19
Norethindrone Approved Phase 4 68-22-4 6230
20
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
21
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
22
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
23
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
24
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
25
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
26
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
27
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
28
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
29
Gliclazide Approved Phase 4 21187-98-4 3475
30
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
31
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
32
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
33
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
34
Ribavirin Approved Phase 4 36791-04-5 37542
35
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
36
Liraglutide Approved Phase 4 204656-20-2 44147092
37
Azathioprine Approved Phase 4 446-86-6 2265
38
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
39
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
40
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
41
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
42
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
43
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
44
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
45
Morphine Approved, Investigational Phase 4 57-27-2 5288826
46
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
47
Radium Ra 223 dichloride Approved, Investigational Phase 4 444811-40-9
48
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
49
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
50
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 2034)
# Name Status NCT ID Phase Drugs
1 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
2 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
3 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
4 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
5 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
6 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
7 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
8 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
9 A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures Unknown status NCT02148848 Phase 4 Risedronate
10 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
11 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
12 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
13 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4 zoledronic acid;sodium chloride
14 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
15 Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Unknown status NCT02792413 Phase 4 Denosumab;NaCl (placebo)
16 Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
17 Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol. Unknown status NCT01908556 Phase 4 Letrozole
18 A Feasibility Study to Explore the Difference in Healing Time Between Teriparatide Treatment and Standard Care on Weber B Ankle Fractures in Older People Unknown status NCT02955056 Phase 4 Forsteo
19 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
20 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
21 A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
22 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
23 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
24 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
25 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
26 Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene Completed NCT00079924 Phase 4 teriparatide;aldrenodate;raloxifene
27 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
28 Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls Completed NCT00168909 Phase 4 alfacalcidol;placebo
29 Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study Completed NCT00549068 Phase 4 Risedronate Sodium (Actonel)
30 Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
31 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
32 Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis Completed NCT00239629 Phase 4 Teriparatide;Strontium ranelate
33 An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
34 Randomized Double-Blind Placebo-Controlled and Parallel Group Study to Evaluate the Impact of One Year Therapy With Monthly Oral Ibandronate 150 mg on Structural Properties of Bone in Postmenopausal Osteoporosis Without Vertebral Fractures Completed NCT00271713 Phase 4 ibandronate, calcium and vitamin D;placebo,calcium and vitamin D
35 A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients Completed NCT02598934 Phase 4 Ibandronate
36 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
37 Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures Completed NCT01709110 Phase 4 Teriparatide;Risedronate;Placebo;Calcium;Vitamin D
38 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
39 Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once Monthly Ibandronate and Once Weekly Risedronate. A Six Month, Two-sequence and Two-period Crossover Study. Completed NCT00377234 Phase 4 Risedronate;ibandronate [Bonviva/Boniva]
40 Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549 Completed NCT00081653 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
41 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
42 A Randomised, Open Label Study to Investigate the Impact of Bone Marker Feedback at 2 Months on Adherence to Monthly Oral Bonviva (Ibandronate) in Women With Post-menopausal Osteoporosis. Completed NCT00545909 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
43 A Randomized Open-Label Study to Investigate the Impact of Bone Marker Feedback at 3 Months on Adherence to Monthly Oral Bonviva in Women With Post-Menopausal Osteoporosis Supported by a Patient Relationship Program Completed NCT00545363 Phase 4 Ibandronate
44 A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women Completed NCT00545051 Phase 4 Placebo;ibandronate
45 A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease. Completed NCT00503113 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva];Alendronate
46 Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis Completed NCT00191425 Phase 4 Teriparatide;Raloxifene
47 The Effects of Teriparatide on Bone Microarchitecture as Determined by High Resolution Magnetic Resonance Imaging and Digital Topological Analysis Completed NCT00557310 Phase 4 teriparatide
48 A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
49 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg Completed NCT00549965 Phase 4 Risedronate Sodium
50 A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women Completed NCT00729651 Phase 4 alendronate sodium (+) cholecalciferol;Comparator: Alendronate sodium (Fosamax)

Search NIH Clinical Center for Osteoporosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Alendronate
Alendronic acid
Bazedoxifene
Calcitonin
calcium acetate
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium Citrate
calcium glubionate
Calcium gluceptate
Calcium Gluconate
CALCIUM GLUCONATE PWDR
Calcium Glycerophosphate
calcium lactate
CALCIUM LEVULINATE
Calcium Pantothenate
calcium phosphate
Cholecalciferol
Conjugated estrogens
Estradiol
Estrone sulfate
Ethinylestradiol
Fluorides
Ibandronate
Levonorgestrel
Medium chain triglycerides
MEDRONATE DISODIUM
Medroxyprogesterone acetate
Norethisterone
Norgestimate
pamidronate
Pamidronate Disodium
Raloxifene
Raloxifene
Raloxifene Hydrochloride
Risedronate
risedronate sodium
Risedronic acid
Romosozumab
salmon calcitonin
Salmon Calcitonin
SODIUM FLUORIDE PWDR
Teriparatide
Teriparatide
Zoledronic acid

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteoporosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteoporosis:
PREOB, autologous osteoblasts for bone disorders

Cochrane evidence based reviews: osteoporosis

Genetic Tests for Osteoporosis

Genetic tests related to Osteoporosis:

# Genetic test Affiliating Genes
1 Postmenopausal Osteoporosis 29 CALCR COL1A1 COL1A2 LRP5 PDLIM4 VDR

Anatomical Context for Osteoporosis

MalaCards organs/tissues related to Osteoporosis:

41
Bone, Breast, Prostate, Testes, Bone Marrow, Kidney, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Osteoporosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Mononucleated Osteoclasts Affected by disease
2 Bone Bone Marrow Multinucleated Osteoclasts Affected by disease
3 Blood Hematopoietic Bone Marrow Osteoclast Precursor Cells Affected by disease

Publications for Osteoporosis

Articles related to Osteoporosis:

(show top 50) (show all 31821)
# Title Authors PMID Year
1
Promoter and intron 1 polymorphisms of COL1A1 interact to regulate transcription and susceptibility to osteoporosis. 9 38 8
19429913 2009
2
Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. 9 38 8
10942433 2000
3
Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. 9 38 8
8841196 1996
4
Genetics of osteoporosis. 38 8
16762578 2006
5
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. 38 8
15908955 2005
6
Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. 9 8
15744038 2005
7
An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. 9 8
14671165 2003
8
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. 38 8
14602752 2003
9
Genetic control of susceptibility to osteoporosis. 38 8
12050200 2002
10
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. 38 8
11889149 2002
11
Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. 38 8
11701687 2001
12
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. 38 8
11344179 2001
13
The genetics of osteoporosis: 'complexities and difficulties'. 38 8
10782923 2000
14
The genetic trail of osteoporosis. 38 8
9535673 1998
15
Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis. 38 8
8053404 1994
16
Mutation in a gene for type I procollagen (COL1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta. 38 71
2052622 1991
17
Reduced bone mass in daughters of women with osteoporosis. 38 8
2915666 1989
18
Effect of medications and epidural steroid injections on fractures in postmenopausal women with osteoporosis. 38 17
31261519 2019
19
Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. 8
26367794 2015
20
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. 8
22504420 2012
21
Multiple genetic loci for bone mineral density and fractures. 8
18445777 2008
22
Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population. 8
17264806 2007
23
Interspecies synteny mapping identifies a quantitative trait locus for bone mineral density on human chromosome Xp22. 8
16183656 2005
24
The effect of calcium supplementation on bone density in premenarcheal females: a co-twin approach. 8
15472185 2004
25
Interaction between vitamin D receptor genotype and estrogen receptor alpha genotype influences vertebral fracture risk. 8
12915669 2003
26
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 8
12908099 2003
27
Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. 8
11061497 2000
28
Vitamin D supplementation in postmenopausal black women. 8
10566638 1999
29
Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. 8
9535665 1998
30
Substitution of glycine-661 by serine in the alpha1(I) and alpha2(I) chains of type I collagen results in different clinical and biochemical phenotypes. 71
8786074 1996
31
Partial isodisomy for maternal chromosome 7 and short stature in an individual with a mutation at the COL1A2 locus. 71
1463018 1992
32
Estrogen status and heredity are major determinants of premenopausal bone mass. 8
1469098 1992
33
Genetic determinants of bone mass in adults. A twin study. 8
3624485 1987
34
A community-based study of the relationship between calcaneal bone mineral density and systemic parameters of blood glucose and lipids. 17
31277108 2019
35
Screening of Bone Density at CT: An Overlooked Opportunity. 17
30917293 2019
36
The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. 9 38
20189618 2010
37
Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. 9 38
20184423 2010
38
Osteocalcin gene polymorphisms influence concentration of serum osteocalcin and enhance fracture identification. 9 38
20200947 2010
39
The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. 9 38
20197302 2010
40
New treatment targets in osteoporosis. 9 38
20381400 2010
41
Biochemical mechanism of gallium on prevention of fatal cage-layer osteoporosis. 9 38
19639269 2010
42
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. 9 38
19874198 2010
43
Effect of glucocorticoid-, parathyroid- and thyroid hormones excess on human iliac crest bone matrix insulin-like growth factor (IGF)-I in patients with osteoporosis. 9 38
19998242 2010
44
Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. 9 38
19673927 2010
45
The association of serum osteoprotegerin and osteoporosis in postmenopausal hemodialysis patients: a pilot study. 9 38
20210559 2010
46
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. 9 38
20116187 2010
47
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. 9 38
20079640 2010
48
Osteoporosis and inflammation. 9 38
20485900 2010
49
Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. 9 38
20061412 2010
50
The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. 9 38
19660583 2010